Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$1.44 +0.09 (+6.85%)
Closing price 04:10 PM Eastern
Extended Trading
$1.45 +0.01 (+0.90%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Key Stats

Today's Range
$1.36
$1.48
50-Day Range
$0.90
$2.05
52-Week Range
$0.90
$3.45
Volume
15,065 shs
Average Volume
11,712 shs
Market Capitalization
$51.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

ARMP MarketRank™: 

Armata Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Armata Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.06% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently increased by 75.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Armata Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for ARMP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

  • Read more about Armata Pharmaceuticals' insider trading history.
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARMP Stock News Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year
See More Headlines

ARMP Stock Analysis - Frequently Asked Questions

Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP shares have decreased by 28.1% and is now trading at $1.4371.
View the best growth stocks for 2025 here
.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The business had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.90 million.

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

Last Earnings
11/14/2023
Today
5/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:ARMP
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+389.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,040,000.00
Pretax Margin
-756.59%

Debt

Sales & Book Value

Annual Sales
$4.53 million
Price / Cash Flow
N/A
Book Value
($0.89) per share
Price / Book
-1.61

Miscellaneous

Free Float
5,247,000
Market Cap
$51.77 million
Optionable
Not Optionable
Beta
0.87
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSEAMERICAN:ARMP) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners